BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-697@pharmaconomics
DTSTAMP:20260707T033824Z
DTSTART;VALUE=DATE:20260327
DTEND;VALUE=DATE:20260328
SUMMARY:URGN PDUFA — ZUSDURI
DESCRIPTION:The FDA's approval decision on ZUSDURI for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) is due Mar 27\, 2026. A green light opens the market\; a complete response letter (CRL) usually sinks the stock.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1668243/000143774926006233/ex_925621.htm\n\nTrack it: https://pharmaconomics.com/e/697
URL:https://pharmaconomics.com/e/697
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:URGN catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR